Jan 03, 2020 (China Knowledge) - China’s biotech company Elpiscience Biopharmaceutical has successfully raised USD 100 mln in its Series B funding round.
Founded in 2017, Shanghai-based Elpiscience is an immunology-driven company that develops cutting-edge immunotherapies to fight cancer. The company has developed a pipeline of over 10 innovative molecules including two IND filing ready assets targeting novel pathways in cancer immunotherapies.
After the completion of the funding round, the company is expected to enhance its research and development of its immunotherapy drug, and invest in pre-clinical and clinical trials of its various drugs.
According to Dr. Darren Ji, co-founder and CEO of Elpiscience, the company will “continuously pursue the exciting journey of developing innovative drugs”, and “stay committed to carefully exploring new scientific discovery towards finding effective therapies for cancer patients”.
The latest funding round was led by investment firm Hyfinity Investments.
Copyright © 2018 www.chinaknowledge.com
Send feedback or comments to: firstname.lastname@example.org
For more news, financial weekly reports, business guides to China and other premium information, subscribe to China Knowledge today: www.chinaknowledge.com
To access our page on Bloomberg, type CKFI